10-Q: Drugs Made In America Acquisition Corp. Reports Q1 2025 Results, Citing Net Income Driven by Trust Account Interest

Drugs Made In America Acquisition Corp. reports a net income of $1,254,543 for the quarter ended March 31, 2025, primarily due to interest earned on its trust account.

Summary

• Drugs Made In America Acquisition Corp., a blank check company, reported its financial results for the quarter ended March 31, 2025.
• The company's net income for the quarter was $1,254,543, primarily driven by $1,585,468 in interest earned on cash and investments held in its trust account.
• General and administrative costs totaled $330,925 for the quarter.
• As of March 31, 2025, the company had $923 in cash and a working capital deficit of $276,350.
• The company's initial public offering (IPO) generated gross proceeds of $200,000,000, and the underwriters exercised their over-allotment option for an additional $30,000,000.
• Simultaneously with the IPO, the company sold Private Placement Units to the Sponsor for $4,000,000, with an additional $300,000 from the sale of over-allotment option units.
• A total of $231,150,000 from the IPO and private placements was placed in a trust account.
• The company has until 21 months from the IPO closing to complete a business combination.
• The company's management has identified a material weakness in internal controls related to inadequate segregation of duties.
• The company's management believes that the mandatory liquidation and subsequent dissolution raises substantial doubt about the company's ability to continue as a going concern within one year after the date that the unaudited financial statements are issued.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company reports a net income, it is primarily due to interest earned on the trust account, which is expected for a SPAC. The going concern uncertainty and material weakness in internal controls are negative factors.

Positives

• The company generated a net income of $1,254,543 for the quarter.
• The trust account generated significant interest income of $1,585,468.
• The IPO and subsequent over-allotment option exercise provided substantial capital of $230,000,000.
• The company has secured $4,300,000 in funding through the sale of Private Placement Units.

Negatives

• The company has a working capital deficit of $276,350 as of March 31, 2025.
• General and administrative costs totaled $330,925 for the quarter.
• The company identified a material weakness in internal controls related to inadequate segregation of duties.
• The company's management believes that the mandatory liquidation and subsequent dissolution raises substantial doubt about the company's ability to continue as a going concern within one year after the date that the unaudited financial statements are issued.

Risks

• The company's ability to continue as a going concern is in doubt due to the mandatory liquidation date.
• Failure to complete a business combination within the allotted time will result in liquidation.
• The identified material weakness in internal controls could lead to financial reporting errors.
• Geopolitical instability, including the Russia-Ukraine conflict and the Israel-Hamas conflict, could adversely affect the company's search for a business combination target.

Future Outlook

The company intends to complete a business combination within 21 months from the closing of the IPO. If a business combination is not completed within this timeframe, the company will liquidate.

Management Comments

• Management plans to address the uncertainty of going concern through a Business Combination.
• Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statement.

Industry Context

This is a standard 10-Q filing for a SPAC, detailing its financial position and activities since its IPO. The company's focus on the pharmaceutical industry aligns with a sector that often attracts significant investment due to its growth potential and innovation.

Comparison to Industry Standards

• SPACs typically hold the majority of their IPO proceeds in a trust account, as Drugs Made In America Acquisition Corp. does with $231,150,000.
• The management fee of $10,000 per month for administrative services is within the typical range for SPACs.
• The 21-month timeframe to complete a business combination is a common structure, although some SPACs may have shorter or longer periods.
• Comparable companies include other pharmaceutical-focused SPACs such as CM Life Science Opportunities and Foresight Acquisition Corp.
• The deferred underwriting fee of 3.0% is a standard arrangement in SPAC IPOs.

Related Party Transactions

• The company pays the Sponsor $10,000 per month for office space and administrative support services.
• The Sponsor provided a promissory note to the Company.
• The Sponsor purchased Private Placement Units.
• The CFO has a consulting agreement with the Company.

Stakeholder Impact

• Shareholders will benefit if the company completes a successful business combination.
• Shareholders face the risk of liquidation if a business combination is not completed.
• The company's employees and service providers are dependent on the company's ability to continue as a going concern.

Next Steps

• The company will continue to seek a business combination target in the pharmaceutical industry.
• The company must complete a business combination within the Combination Period.
• The company needs to address the identified material weakness in internal controls.

Key Dates

Keywords

business combination, SPAC, trust account, IPO, pharmaceutical, acquisition, blank check company, redemption, underwriting, sponsor